EHA 2018 | Physicians must perform molecular monitoing regularly for successful outcomes in CML
Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, talks about the TARGET survey, a survey of real-world management of chronic myeloid leukemia (CML) across 33 countries. This survey looked at how physicians chose front-line therapy and selected who would be eligible for treatment-free remission, as well as their practice of molecular monitoring. Dr Hughes explains that there is a concern, as many physicians reported that they are not able to perform molecular monitoring on a regular basis. This has an impact on the likelihood of successful outcomes in CML, so it is important for physicians to monitor their patients regularly. This interview was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
